FDA Approves GSK’s Anoro Ellipta, The First LABA/LAMA Combination
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved GSK’s Anoro Ellipta as the first LABA/LAMA combination product in the U.S. for the maintenance treatment of COPD Dec. 18, positioning GSK to launch a second respiratory product months after launching Breo Ellipta.
You may also be interested in...
FLAME Shoots LABA/LAMA Combos Up To First Choice In COPD
At the American Thoracic Society annual meeting, science committee chair says change in COPD treatment guidelines to favor LABA/LAMA as preferred option will be considered soon.
Boehringer Enters Asthma Market With New Indication For Spiriva Respimat
Spiriva – the first long-acting muscarinic antagonist approved for asthma – wins broad indication; sales target is likely sizeable patient population with uncontrolled disease.
Novartis Respiratory Franchise Sits On FDA Launch Pad; Can It Achieve Orbit?
EXPEDITION clinical program seems to satisfy U.S. requirements for firm’s COPD bronchodilators; now all Novartis needs is approval, some clinical differentiation – and perhaps a marketing partner.